Takeda Faces $2.46 Billion Jury Verdict in AMITIZA Antitrust Case; Plans Appeal
TAK sits 28% above its 52-week low of $12.99.
Summary
Takeda was hit with a nearly $2.5 billion potential liability from a U.S. antitrust jury verdict related to its AMITIZA drug, which the company plans to appeal.
Key Events · Legal and Risk Events · TAK
-
Jury Verdict Against Takeda
A U.S. jury found Takeda liable in the AMITIZA antitrust litigation, awarding plaintiffs $884.9 million in single damages.
-
Potential Trebled Damages
Approximately $2.46 billion of the awarded damages (for wholesaler and retailer classes) will be automatically trebled under U.S. antitrust law. Damages for the end payor class are subject to further proceedings.
-
Company Plans Appeal
Takeda stated it will vigorously pursue post-trial motions and an appeal, believing the case lacks merit and citing evidentiary and legal errors.
-
Financial Statement Revision
Takeda will recognize a provision in its FY2025 consolidated financial statements, requiring a revision and re-filing of its FY2025 earnings report.
Analysis · TAK · Life Sciences
A U.S. jury found Takeda liable in an antitrust lawsuit related to its AMITIZA drug, awarding plaintiffs $884.9 million in single damages. A significant portion of these damages, totaling approximately $2.46 billion, will be automatically trebled under U.S. antitrust law. While Takeda plans to vigorously appeal the verdict and states no impact on core financial results, the company will need to recognize a substantial provision in its FY2025 financial statements, leading to a revision of its earnings report and potentially impacting adjusted free cash flow. This represents a major legal and financial setback.
At the time of this filing, TAK was trading at $16.57 on NYSE in the Life Sciences sector, with a market capitalization of approximately $52.4B. The 52-week trading range was $12.99 to $18.90. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.